Rilmazafone hydrochloride

• CAT Number: I020582
• CAS Number: 85815-37-8
• Molecular Formula: C21H21Cl3N6O3
• Molecular Weight: 511.79
• Purity: ≥95%
• Synonyms: 5-[[(2-aminoacetyl)amino]methyl]-1-[4-chloro-2-(2-chlorobenzoyl)phenyl]-N,N-dimethyl-1,2,4-triazole-3-carboxamide;hydrochloride
• InChI: InChI=1S/C21H20Cl2N6O3.ClH/c1-28(2)21(32)20-26-17(11-25-18(30)10-24)29(27-20)16-8-7-12(22)9-14(16)19(31)13-5-3-4-6-15(13)23;/h3-9H,10-11,24H2,1-2H3,(H,25,30);1H
• InChIKey: KHINGHZNENOVFD-UHFFFAOYSA-N
• SMILES: CN(C)C(=O)C1=NN(C(=N1)CNC(=O)CN)C2=C(C=C(C=C2)Cl)C(=O)C3=CC=CC=C3Cl.Cl

Rilmazafone hydrochloride（Cat No.:I020582）is a prodrug-type sedative-hypnotic belonging to the benzodiazepine class, with the molecular formula C21H22Cl2N4O3·HCl. It is inactive until metabolized in the body, where it is converted to active benzodiazepine derivatives that act on GABAA receptors, enhancing inhibitory neurotransmission. Used primarily in Japan for the treatment of insomnia, rilmazafone promotes sleep with fewer residual effects compared to traditional benzodiazepines. It is typically administered orally and is known for its relatively short half-life. Common side effects include drowsiness, dizziness, and mild cognitive impairment. It is not approved in many countries outside Japan.

Reference

[1]. Yasui M, et al. [Pharmacological profiles of benzodiazepinergic hypnotics and correlations with receptor subtypes]. Nihon Shinkei Seishin Yakurigaku Zasshi. 2005 Jun;25(3):143-51.
[Content Brief]

[2]. Matsubara T, et al. Effect of change of hepatic drug-metabolizing activity on plasma concentrations of major metabolites of the new sleep inducer 450191-S, a 1H-1,2,4-triazolyl benzophenone derivative. Jpn J Pharmacol. 1987 Aug;44(4):429-36.
[Content Brief]